Formulary Watch Newsletter

To view this email as a web page, click here.

First generic Nasonex available

FDA approved the first generic version of Nasonex nasal spray (mometasone furoate monohydrate, Apotex Corp).

Gilead promises generic versions of new hepatitis drug

After Gilead Sciences received FDA approval for a new drug for chronic hepatitis B virus, it said low-cost, generic versions would also soon be available.

Find out more

FDA moves forward with approval of generic Abilify from 4 different manufacturers despite Otsuka pushback

FDA’s approval of generic versions of Abilify (aripiprazole), an antipsychotic drug approved to treat schizophrenia and bipolar disorder, from 4 different generic manufacturers, had industry insiders pondering the generic drug market.

FDA approves first generic Truvada for HIV

FDA approved the first generic version of Gilead’s Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1, in combination with other antiretroviral agents, as well as for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to prevent sexually acquired HIV infection in adults at high risk.

First generic Strattera for ADHD approved

FDA approved the first generic versions of Strattera (atomoxetine) for the treatment of attention deficit/hyperactivity disorder.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

CONNECT